Cargando…

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients. It is also acknowledged as an independent risk factor for cardiovascular disease (CVD). Since sitagliptin was approved, many studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Mega, Cristina, Teixeira-de-Lemos, Edite, Fernandes, Rosa, Reis, Flávio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643039/
https://www.ncbi.nlm.nih.gov/pubmed/29098166
http://dx.doi.org/10.1155/2017/5164292
_version_ 1783271455860981760
author Mega, Cristina
Teixeira-de-Lemos, Edite
Fernandes, Rosa
Reis, Flávio
author_facet Mega, Cristina
Teixeira-de-Lemos, Edite
Fernandes, Rosa
Reis, Flávio
author_sort Mega, Cristina
collection PubMed
description Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients. It is also acknowledged as an independent risk factor for cardiovascular disease (CVD). Since sitagliptin was approved, many studies have been carried out revealing its ability to not only improve metabolic control but also ameliorate dysfunction in various diabetes-targeted organs, especially the kidney, due to putative underlying cytoprotective properties, namely, its antiapoptotic, antioxidant, anti-inflammatory, and antifibrotic properties. Despite overall recommendations, many patients spend a long time well outside the recommended glycaemic range and, therefore, have an increased risk for developing micro- and macrovascular complications. Currently, it is becoming clearer that type 2 diabetes mellitus (T2DM) management must envision not only the improvement in glycaemic control but also, and particularly, the prevention of pancreatic deterioration and the evolution of complications, such as DN. This review aims to provide an overview of the current knowledge in the field of renoprotective actions of sitagliptin, namely, improvement in diabetic dysmetabolism, hemodynamic factors, renal function, diabetic kidney lesions, and cytoprotective properties.
format Online
Article
Text
id pubmed-5643039
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-56430392017-11-02 Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes Mega, Cristina Teixeira-de-Lemos, Edite Fernandes, Rosa Reis, Flávio J Diabetes Res Review Article Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients. It is also acknowledged as an independent risk factor for cardiovascular disease (CVD). Since sitagliptin was approved, many studies have been carried out revealing its ability to not only improve metabolic control but also ameliorate dysfunction in various diabetes-targeted organs, especially the kidney, due to putative underlying cytoprotective properties, namely, its antiapoptotic, antioxidant, anti-inflammatory, and antifibrotic properties. Despite overall recommendations, many patients spend a long time well outside the recommended glycaemic range and, therefore, have an increased risk for developing micro- and macrovascular complications. Currently, it is becoming clearer that type 2 diabetes mellitus (T2DM) management must envision not only the improvement in glycaemic control but also, and particularly, the prevention of pancreatic deterioration and the evolution of complications, such as DN. This review aims to provide an overview of the current knowledge in the field of renoprotective actions of sitagliptin, namely, improvement in diabetic dysmetabolism, hemodynamic factors, renal function, diabetic kidney lesions, and cytoprotective properties. Hindawi 2017 2017-08-27 /pmc/articles/PMC5643039/ /pubmed/29098166 http://dx.doi.org/10.1155/2017/5164292 Text en Copyright © 2017 Cristina Mega et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Mega, Cristina
Teixeira-de-Lemos, Edite
Fernandes, Rosa
Reis, Flávio
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
title Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
title_full Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
title_fullStr Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
title_full_unstemmed Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
title_short Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
title_sort renoprotective effects of the dipeptidyl peptidase-4 inhibitor sitagliptin: a review in type 2 diabetes
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643039/
https://www.ncbi.nlm.nih.gov/pubmed/29098166
http://dx.doi.org/10.1155/2017/5164292
work_keys_str_mv AT megacristina renoprotectiveeffectsofthedipeptidylpeptidase4inhibitorsitagliptinareviewintype2diabetes
AT teixeiradelemosedite renoprotectiveeffectsofthedipeptidylpeptidase4inhibitorsitagliptinareviewintype2diabetes
AT fernandesrosa renoprotectiveeffectsofthedipeptidylpeptidase4inhibitorsitagliptinareviewintype2diabetes
AT reisflavio renoprotectiveeffectsofthedipeptidylpeptidase4inhibitorsitagliptinareviewintype2diabetes